TY - JOUR
T1 - Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes
AU - Serna-Muñoz, Ricardo
AU - Hernández-Terán, Alejandra
AU - Soto-Nava, Maribel
AU - Tapia-Trejo, Daniela
AU - Ávila-Ríos, Santiago
AU - Mejía-Nepomuceno, Fidencio
AU - García, Emma
AU - Castillejos-López, Manuel
AU - Higuera-Iglesias, Anjarath Lorena
AU - Aquino-Gálvez, Arnoldo
AU - Thirion-Romero, Ireri
AU - Pérez-Padilla, Rogelio
AU - Aguilar-Faisal, José Leopoldo
AU - Vázquez-Pérez, Joel Armando
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations in severe COVID-19 cases. Until now, the importance of developing a neutralizing antibody response in the acute phase and its relationship with progression to severe disease or fatal outcome among hospitalized patients remains unclear. In this study, we aim to characterize and compare longitudinally the primary humoral immune host response in the early stages of the disease, looking for an association between neutralization, antibody titers, infective viral lineage, and the clinical outcome in hospitalized and non-hospitalized patients. A total of 111 patients admitted at INER from November 2021 to June 2022 were included. We found that patients with negative or low neutralization showed a significant reduction in survival probability compared to patients with medium or high neutralization. We observed a significant decrease in the median of neutralization in patients infected with viral variants with changes in RBD of the spike protein. Our results suggest that developing an early and robust neutralizing response against SARS-CoV-2 may increase survival probability in critical patients.
AB - The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations in severe COVID-19 cases. Until now, the importance of developing a neutralizing antibody response in the acute phase and its relationship with progression to severe disease or fatal outcome among hospitalized patients remains unclear. In this study, we aim to characterize and compare longitudinally the primary humoral immune host response in the early stages of the disease, looking for an association between neutralization, antibody titers, infective viral lineage, and the clinical outcome in hospitalized and non-hospitalized patients. A total of 111 patients admitted at INER from November 2021 to June 2022 were included. We found that patients with negative or low neutralization showed a significant reduction in survival probability compared to patients with medium or high neutralization. We observed a significant decrease in the median of neutralization in patients infected with viral variants with changes in RBD of the spike protein. Our results suggest that developing an early and robust neutralizing response against SARS-CoV-2 may increase survival probability in critical patients.
KW - SARS-CoV-2
KW - neutralizing antibodies
KW - severity
KW - variants
UR - http://www.scopus.com/inward/record.url?scp=85144723425&partnerID=8YFLogxK
U2 - 10.3390/vaccines10122063
DO - 10.3390/vaccines10122063
M3 - Artículo
C2 - 36560474
AN - SCOPUS:85144723425
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 12
M1 - 2063
ER -
